Harvard Bioscience Inc
HBIOHarvard Bioscience Inc (HBIO) is a global developer and manufacturer of biomedical research and clinical products. The company offers equipment and tools used in life sciences research, including instruments for cell analysis, laboratory automation, and tissue culture. Harvard Bioscience serves academic, government, and industry customers by supporting advances in biomedical research and drug development.
Company News
Harvard Bioscience reported Q2 2025 GAAP revenue of $20.5 million, exceeding analyst expectations by 9.3% despite an 11.3% year-over-year decline. The company showed improved operational cash flow and continued focus on new product development in biomedical research technologies.
Harvard Bioscience announced the appointment of John Duke to its board of directors and the retirement of Thomas Loewald. The company also reported its first quarter 2025 financial results.
Harvard Bioscience reported Q1 2025 results with revenues of $21.8 million, down from $24.5 million in Q1 2024. The company recorded a net loss of $50.3 million, which included a $48 million goodwill impairment. Adjusted EBITDA was $0.8 million, down from $1.6 million in the prior year quarter.
Harvard Bioscience announced the resignation of its Chief Financial Officer Jennifer Cote, effective upon the filing of the company's Q1 2025 report. The company has appointed Mark Frost as Interim CFO, who brings over 30 years of financial and executive experience.
Harvard Bioscience, a leading developer of life science technologies, announced its participation in two investor conferences in March 2025, where the company's management will host one-on-one meetings and fireside chats.
